Pancreatic Cancer Research

ResearcherPeking University First HospitalNo recent work listed

Zhengkui Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3348-5281; OpenAlex author ID A5064167555. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2016: 2 papers · 2017: 1 paper · 2018: 4 papers · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper

Papers 12

  1. Exosomal miR-485-3p derived from pancreatic ductal epithelial cells inhibits pancreatic cancer metastasis through targeting PAK1. Co-author DOI 10.1097/cm9.0000000000002154↗
  2. Inhibition of bone morphogenetic protein receptor 2 suppresses pancreatic ductal adenocarcinoma growth by regulating GRB2/PI3K/AKT axis. Co-author DOI 10.21037/atm-20-2194↗
  3. Molecular characterization of circulating tumor cells in pancreatic ductal adenocarcinoma: potential diagnostic and prognostic significance in clinical practic… Co-author DOI 10.21037/hbsn-20-383↗
  4. LncRNA H19-Derived miR-675-3p Promotes Epithelial-Mesenchymal Transition and Stemness in Human Pancreatic Cancer Cells by targeting the STAT3 Pathway. Co-author DOI 10.7150/jca.44833↗
  5. BRM transcriptionally regulates miR-302a-3p to target SOCS5/STAT3 signaling axis to potentiate pancreatic cancer metastasis. Co-author DOI 10.1016/j.canlet.2019.02.031↗
  6. Demethylzeylasteral (ZST93) inhibits cell growth and enhances cell chemosensitivity to gemcitabine in human pancreatic cancer cells via apoptotic and autophagi… Co-author DOI 10.1002/ijc.31211↗
  7. Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer … Co-author DOI 10.1021/acsnano.8b01573↗
  8. Long non-coding RNA MEG3 functions as a tumour suppressor and has prognostic predictive value in human pancreatic cancer. Co-author DOI 10.3892/or.2018.6178↗
  9. Long noncoding RNA H19 derived miR-675 regulates cell proliferation by down-regulating E2F-1 in human pancreatic ductal adenocarcinoma. Co-author DOI 10.7150/jca.21347↗
  10. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling. Co-author DOI 10.1016/j.canlet.2017.05.006↗
  11. The long noncoding RNA H19 promotes cell proliferation via E2F-1 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/15384047.2016.1219814↗
  12. Hedgehog Signaling Regulates Epithelial-Mesenchymal Transition in Pancreatic Cancer Stem-Like Cells. Co-author DOI 10.7150/jca.13305↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yinmo Yang · 11 shared papers, 2016–2022 · strength 1.09
  2. Xiaodong Tian · 8 shared papers, 2016–2022 · strength 0.71
  3. Ling Ma · 8 shared papers, 2016–2022 · strength 0.70
  4. Feng Wang · 7 shared papers, 2016–2022 · strength 0.58
  5. Huahu Guo · 5 shared papers, 2017–2021 · strength 0.46
  6. Xiaodong Tian · 4 shared papers, 2016–2021 · strength 0.44
  7. Chong Du · 6 shared papers, 2016–2019 · strength 0.44
  8. Marko Kornmann · 6 shared papers, 2016–2019 · strength 0.43
  9. Yongsu Ma · 3 shared papers, 2018–2021 · strength 0.35
  10. Yazhou Wang · 2 shared papers, 2018–2021 · strength 0.22
  11. Mingzhe Li · 1 shared paper, 2022 · strength 0.16
  12. Xiu Rong Dong · 1 shared paper, 2021 · strength 0.15
  13. Xudong Zhao · 1 shared paper, 2021 · strength 0.15
  14. Xiaohang Zhao · 1 shared paper, 2021 · strength 0.15
  15. Xiaoran Liu · 2 shared papers, 2016–2017 · strength 0.13
  16. Long Rong · 1 shared paper, 2020 · strength 0.11
  17. Feng Wang · 1 shared paper, 2020 · strength 0.11
  18. Yazhou Wang · 1 shared paper, 2019 · strength 0.09
  19. Feng Wang · 1 shared paper, 2018 · strength 0.09
  20. Yinmo Yang · 1 shared paper, 2018 · strength 0.07
  21. Xiao Zhao · 1 shared paper, 2018 · strength 0.07
  22. Guangjun Nie · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.